Collaboration and Licensing Agreements (Narrative) (Details) $ in Millions		12 Months Ended
	Jan. 30, 2015 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jan. 08, 2016 drugs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent consideration liability		$ 375.0	$ 199.7	$ 223.6
Proceeds from sale of assets and subsidiaries		1,950.0	96.7	$ 20.0
Momenta
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of drugs | drugs					6
Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments		18.5
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Revance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development			$ 30.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development		50.0
Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments		347.0
Maximum | Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments	$ 293.0
Fiscal Year 2017 | Maximum | Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments		38.0
Respiratory delivery platform [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent consideration liability		$ 132.0